Overview


According to FutureWise analysis the market for diabetic retinopathy in 2023 is US$ 8.85 billion, and is expected to reach US$ 14.78 billion by 2031 at a CAGR of 6.6%.

Diabetic retinopathy is one of the most severe complications caused by diabetes, which can have a significant impact on the blood vessels in the retina. The retina is an important tissue located at the rear of the eye that is crucial for detecting light. This condition is a frequent cause of blindness in adults and can cause permanent vision loss if left untreated. Diabetic retinopathy affects both type 1 and type 2 diabetes patients, with the risk increasing the longer a patient has diabetes. In diabetic retinopathy, the high blood sugar levels associated with diabetes can damage the small blood vessels in the retina. This can cause the blood vessels to leak, leading to swelling and fluid build-up in the retina, which can impair vision. Over time, the damaged blood vessels can also cause abnormal growth of new blood vessels, which can bleed and cause scarring, leading to further vision loss.

Diabetic retinopathy can be classified into two types: non-proliferative and proliferative. Non-proliferative diabetic retinopathy is the early stage of the disease, in which the blood vessels in the retina become damaged, causing small bulges or microaneurysms to form. As the disease progresses, the blood vessels can become blocked, leading to areas of the retina that do not receive enough oxygen and nutrients. This can cause the retina to produce new blood vessels, leading to more severe proliferative diabetic retinopathy. Proliferative diabetic retinopathy signifies an advanced stage of diabetes that triggers the emergence of anomalous blood vessels on the retinal or optic nerve surface. These new blood vessels are delicate and can rupture swiftly, leading to bleeding inside the eye that ultimately results in vision loss. In severe cases, the new blood vessels can also cause scarring, leading to a detachment of the retina from the rear of the eye, which can cause blindness.

FutureWise Market Research has published a report that provides an insightful analysis of Diabetic Retinopathy Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Diabetic Retinopathy Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer, Inc.
  • Bayer AG
  • Alimera Science, Inc.
  • Allergan plc
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Oxurion NV
  • BCN Peptides
  • Sirnaomics Inc.
  • Valeant Pharmaceuticals International, Inc
  • Genentech
  • Kowa Company, Ltd.
  • Abbvie, Inc.
  • Ampio Pharmaceuticals, Inc.
  • F-Hoffmann-La Roche Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Diabetic Retinopathy Market:

In June 2022, According to Regeneron Pharmaceuticals, Inc., the EYLEA (aflibercept) Injectable Supplemental Biologics Permit Application for every 16-week 2 mg dosing schedule in patients with diabetic retinopathy was approved by the United States Food and Drug Administration.

Diabetic retinopathy (DR) is a severe complication of diabetes that can lead to blindness or vision loss. The market for treatments related to diabetic retinopathy is constantly changing, and multiple factors influence its growth and demand. One of the major drivers of the diabetic retinopathy market is the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, by 2045, there will be 700 million individuals worldwide with diabetes, up from the current 463 million. As diabetes is the leading cause of diabetic retinopathy, this increase is expected to drive the demand for diabetic retinopathy treatments. The rise in the aging population is also a significant driver of the diabetic retinopathy market. As people age, their risk of developing diabetes and diabetic retinopathy increases. The global aging population is expected to reach 1.5 billion by 2050, which is expected to further increase the demand for diabetic retinopathy treatments. The increasing awareness among patients and healthcare professionals about diabetic retinopathy is another factor that is driving the market. As people become increasingly aware of the possible complications of diabetes, they are more likely to seek early diagnosis and treatment of diabetic retinopathy, which is expected to fuel the demand for diabetic retinopathy treatments.

On the other hand, there are several challenges in the diabetic retinopathy market. One of the main challenges is the high cost of diabetic retinopathy treatments. A large number of patients, especially in low- and middle-income countries, are unable to bear the cost of these treatments, which limits the growth of the market. Another challenge is the lack of trained healthcare professionals and infrastructure in many countries. Diabetic retinopathy requires specialized screening and treatment, which may not be available in some regions. This limits the access of patients to diabetic retinopathy treatments and affects the growth of the market.

By Type

  • Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema (DME)

By Treatment Type

  • Anti VEGF Drug
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy

By Distribution Channel

  • Hospitals & Pharmacies
  • Eye Clinics
  • Ambulatory Surgical Centers (ASCs)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. In the upcoming years, North America is predicted to experience significant growth due to various factors, including a rise in cases of diabetes and blindness, advancements in diabetic retinopathy surgical instruments, and an increasing elderly population. The prevalence of diabetes in North America has been increasing over the past decade. Diabetic retinopathy is a danger for people with diabetes. The main factor contributing to new instances of blindness in individuals in the United States between the ages of 20 and 74 is diabetic retinopathy. The Centres for Disease Control and Prevention (CDC) estimates that in 2021, over 4.1 million Americans had diabetic retinopathy, and nearly 900,000 were at risk for vision-damaging retinopathy. Consequently, it is anticipated that the rising number of people with diabetic retinopathy will aid in expanding the market nationwide.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Diabetic Retinopathy Market By Type, By Treatment Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com.

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Diabetic Retinopathy Market Variables, Trends and Scope
    •     1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Diabetic Retinopathy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Diabetic Retinopathy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Diabetic Retinopathy Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Proliferative Diabetic Retinopathy
        2. Diabetic Macular Edema (DME)

  • 8.   Diabetic Retinopathy Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anti VEGF Drug
        2. Steroid Implants
        3. Laser Surgeries
        4. Vitrectomy

  • 9.  Diabetic Retinopathy Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals & Pharmacies
        2. Eye Clinics
        3. Ambulatory Surgical Centers (ASCs)

  • 10.   North America Diabetic Retinopathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Diabetic Retinopathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Diabetic Retinopathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Diabetic Retinopathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
                 2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bayer AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Alimera Science, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan plc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Regeneron Pharmaceuticals, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Oxurion NV
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. BCN Peptides.
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sirnaomics Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Valeant Pharmaceuticals International, Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Genentech
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Kowa Company, Ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Abbvie, Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Ampio Pharmaceuticals, Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. F-Hoffmann-La Roche Ltd.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients